Literature DB >> 1534715

Amlodipine compared to nitrendipine in hypertensive patients: the effects on toleration in relationship to the onset of action.

B Waeber1, E T Borges, P Christeler, M Guillaume-Gentil, U Hollenstein, M Mannhart.   

Abstract

Amlodipine and nitrendipine are calcium antagonists of the 1,4-dihydropyridine group which differ in their pharmacokinetic and pharmacodynamic properties. The clinical relevance of these differences was investigated in a study designed to compare the efficacy and safety of once-daily amlodipine (5 mg) and nitrendipine (20 mg) in patients with mild-to-moderate essential hypertension. Ambulatory blood pressure monitoring and conventional measurements showed that amlodipine and nitrendipine produced comparable reductions in blood pressure after 4 weeks of treatment. However, the onset of the antihypertensive effect was gradual for amlodipine, while most of the reduction achieved at the end of treatment with nitrendipine was seen after the first dose. There were no significant changes in heart rate with amlodipine, but significant increases occurred during the first 6 h of nitrendipine treatment. Amlodipine was associated with a significantly lower incidence of vasodilator-related adverse effects at initiation of therapy (headache, flushing, tachycardia) compared with nitrendipine, which may reflect its slower onset of action. The different pharmacodynamic and toleration profiles of amlodipine and nitrendipine at therapeutically equivalent doses suggest that amlodipine may have advantages in the treatment of hypertension, especially in terms of the low incidence of acute side effects, which may ultimately translate into improved patient compliance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1534715     DOI: 10.1159/000175047

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  3 in total

1.  At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild-to-moderate hypertension: a double-blind, randomized, parallel-group study.

Authors:  L Hermans; A Deblander; P De Keyser; I Scheys; E Lesaffre; K J Westelinck
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

Review 2.  Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease.

Authors:  M Haria; A J Wagstaff
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

Review 3.  The effect of antihypertensive treatment on headache and blood pressure variability in randomized controlled trials: a systematic review.

Authors:  Alastair John Stewart Webb; Peter Malcolm Rothwell
Journal:  J Neurol       Date:  2012-02-22       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.